243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection
The Readout Loud
00:00
The FDA Reimbursement for Alzheimer's Drugs
There was speculation that there was something that the FDA had seen, some kind of safety signal that made them want to delay. But we'll know a lot more about the safety and the efficacy of Dana-Mab when that phase three study come out. Medicare is not yet reimbursing these drugs in any kind of broad way. So perhaps that doesn't really change the ballgame there.
Transcript
Play full episode
